Union Korea Pharm Calls Extraordinary General Meeting for Complete Board Overhaul Under Rehabilitation Plan, Balancing Hope for Normalization with Uncertainty
Union Korea Pharm will convene an extraordinary general meeting under court-approved rehabilitation plan Chapter 13 to appoint four new directors and remove seven existing directors.
New inside directors include Seong Gwang-hyun from OCI Holdings and Kim Seong-su from Bukwang Pharmaceutical. New outside directors include Yonsei University professor Lim Jeong-su and law firm Jipyong's Min Byung-hwan, aiming for financial restructuring and management normalization.
While being under rehabilitation poses investment risk, the new directors' expertise may positively impact management stability. No capital changes or shareholder dilution plans have been disclosed so far.
[AI Summary]Union Korea Pharm shows commitment to normalization through a complete board change under court-led rehabilitation, but uncertainty over the rehabilitation plan details and potential capital adjustments leads to a neutral short-term stock price outlook.
KOSDAQ Filing Information
Resolution to Convene a General Meeting of Shareholders (Extraordinary General Meeting)